ACIP changes, new court rulings, and coverage gaps threaten vaccines, pharmacists’ reimbursement, and children's access through Vaccine For Children.
|Slideshows|October 15, 2018
- Drug Topics October 2018
- Volume 162
- Issue 10
Top 5 Ways to Make Vaccinations Less Frustrating
Author(s)Jennifer Gershman, PharmD, CPh
Flu vaccinations can take up lots of your already-busy schedule, but that doesn’t mean they’re not important.
Advertisement
Articles in this issue
over 7 years ago
Lower Drug Prices Aren’t Worth Higher Health Risksalmost 8 years ago
How to Talk About Being a Pharmacistalmost 8 years ago
What it’s Like to Be an Oncology Pharmacistalmost 8 years ago
The 4 Tech Advances Benefitting Pharmacies and Patientsalmost 8 years ago
How Mergers Will Affect Pharmacistsalmost 8 years ago
Negotiating Better Hours: A Guide for Pharmacistsalmost 8 years ago
How to Create the Job You Wantalmost 8 years ago
More Pharmacists Move into Medical Practices, More Doctors See Valuealmost 8 years ago
The 4 Keys to Medication Adherencealmost 8 years ago
The Best Pharmacies, New Pharmacy Degrees, and More NewsAdvertisement
Related to this article
Madeline Sutton, MD, MPH, FACOG, joins to discuss risks of HPV infection among women and how pharmacists can improve outcomes in this area.
The expert explains 2025-1016 flu, COVID-19, and RSV vaccine updates from AAP, ACOG, AAFP, and IDSA, and what changing schedules mean for pharmacists.
An analysis found all-cause pneumonia Black, lower-income, and medically at-risk children still face substantially higher rates of hospitalization.
A cross-sectional survey links chronic fatigue, cognitive impairment, and menstrual irregularity to COVID-19 vaccination, with rates differing by brand.
Thomas Lew, MD, ABIM, Molly O’Shea, MD, FAAP, and Jesse Goodman, MD, MPH, discuss vaccine policy changes and their impact on measles outbreaks.
Jesse Goodman, MD, MPH, provides nuance regarding HHS’ suggestion to separate MMR combination vaccines as well as the looming elimination status review in November.
A population-level analysis finds that age, comorbidity burden, and long-term care residence continue to drive severe outcomes.
Advertisement
Advertisement
Trending on Drug Topics
1
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
2
Study Finds No Neurodevelopmental Risk in Prenatal COVID-19, Except Speech
3
Oveporexton Met Primary, Key Secondary End Points in Phase 3 Studies
4
GLP-1 Prescribing Rose Among Adults With Serious Mental Illness
5